Merck KGaA’s Stimuvax Is First Therapeutic Vaccine For Lung Cancer In Phase III
June 21st, 2006
A therapeutic vaccine being developed for non-small cell lung cancer should be going into Phase III testing this autumn.
THE SURVIVAL RATE OF LC IS 15.5%.
THAT’S UNACCEPTABLE. WE’RE
HERE TO CHANGE THAT.